Galapagos abandons Cell Therapy, Signaling a Shift in Big Pharma’s Approach
A wave of strategic re-evaluations is sweeping through the pharmaceutical industry, and Galapagos NV is the latest major player to step back from cell therapy advancement. Recently,the company announced it will discontinue its cell therapy programs,a decision that mirrors similar moves by industry giants like AstraZeneca,AbbVie,and Gilead Sciences. This shift highlights a growing reassessment of the complexities and costs associated with this promising, yet challenging, field.
A Growing trend: Why the Retreat from Cell Therapy?
Several factors are driving this trend. You’re seeing big pharma increasingly favor in vivo cell therapies – those administered directly into the body – over ex vivo approaches. Ex vivo therapies, like those Galapagos was developing, require cells to be modified outside the body before being reintroduced, demanding significant infrastructure and expertise.
Here’s a breakdown of recent activity:
* AstraZeneca acquired Esobiotec, bolstering its in vivo cell therapy capabilities.
* AbbVie moved to acquire Capstan Immunology, another in vivo cell therapy startup.
* Gilead Sciences expanded its portfolio with the acquisition of kite and Interius.
* Takeda Pharmaceutical announced a complete halt to its cell therapy research.
* Novo Nordisk also decided to discontinue its cell therapy programs as part of a broader restructuring.
These acquisitions and abandonments suggest a strategic pivot toward therapies that are potentially easier to manufacture and deliver, while still offering the promise of treating complex diseases. Importantly, these in vivo platforms also open doors to treating autoimmune disorders, expanding the potential market.
Galapagos’ Decision: A Unanimous Vote & Significant Impact
The Galapagos board unanimously approved the wind-down of its cell therapy buisness, with two Gilead-appointed directors abstaining from the vote. While the company will entertain acquisition offers for its cell therapy assets during the wind-down, the decision signals a clear change in direction.
This move will sadly result in the closure of facilities across multiple continents:
* Leiden, Netherlands & Basel, Switzerland (Europe)
* Princeton, New Jersey & Pittsburgh, Pennsylvania (U.S.)
* Shanghai, China
Approximately 365 employees will be affected by these closures. Galapagos will maintain its headquarters in Mechelen, Belgium, and focus on rebuilding its pipeline.
Financial Implications & Future Outlook
Galapagos currently holds a robust cash position of €3.1 billion (approximately $3.6 billion). This capital will be crucial for forging new business deals and developing a refreshed pipeline under the leadership of newly appointed CEO, Henry Gosebruch, who succeeded Paul Stoffels in May.
you can expect some financial impact:
* Operating Costs: €100-€125 million from Q4 2025 through 2026.
* Restructuring Costs: €150-€200 million in 2026.
An updated cash outlook will be provided alongside the company’s Q3 2025 earnings report in early November.
What Does This Mean for the Future of Cell Therapy?
Galapagos’ decision, alongside those of its peers, doesn’t necessarily spell the end of cell therapy. Instead, it represents a period of recalibration. The industry is learning that not all cell therapy approaches are created equal.
For you, as an investor or healthcare professional, this means a greater focus on in vivo therapies and a more pragmatic approach to development.It also underscores the importance of strong financial backing and a clear path to commercialization in this rapidly evolving field. The future of cell therapy will likely be defined by efficiency, scalability, and a targeted approach to disease treatment.
(Image: Ekkaluck, Getty Images)